28 November 2021
On 8-10 November 2021, Dr Naveen Rao, Senior Vice President, Health and other senior representatives from The Rockefeller Foundation joined World Health Organization (WHO) representatives to review the strategic directions of collaboration between the two Organizations. Notably they discussed support for the WHO Health Emergencies Programme and the Science Division, including the WHO Hub on for Pandemic and Epidemic Intelligence, genomic surveillance, infodemiology, vaccine equity and demand generation and WHO’s ongoing work with philanthropic organizations.
”The Rockefeller Foundation and WHO have worked together to address global health challenges since WHO was first established,” said Ms Jane Ellison, Executive Director, External Relations and Governance. ”The support of the Foundation has been – and will continue to be – fundamental, helping WHO to make major advances in providing equitable health outcomes for all.”
The Rockefeller Foundation’s collaboration with WHO dates back to when the WHO constitution was first created. Over the past two decades, The Rockefeller Foundation has continued to be a key collaborator, providing over US$ 25.3 million in support to WHO programmes.
Recent collaboration has focused on digital health building capacity in data and innovation to protect and promote health and well-being. Throughout the COVID-19 pandemic, the two Organizations worked together towards the goal of maintaining essential health services everywhere, expanding virus testing capacity, strengthening and accelerating the digitalization of WHO guidelines, and advancing approaches to using digital products to end the current pandemic and prevent future ones. The Rockefeller Foundation and WHO currently co-lead the Access to COVID-19 Tools Accelerator (ACT-A) Genomic Surveillance Working Group.
“The Rockefeller Foundation recognizes WHO’s unique and vital role in safeguarding global health and well-being,” said Dr Naveen Rao, Senior Vice President, Health, The Rockefeller Foundation. “We remain steadfast in our commitment to support WHO to be a strong and efficient Organization.”
The overall objectives of the strategic dialogue were for the two Organizations to gain a better understanding of each other’s current work and priorities, and explore expanded areas for collaboration based on a more deliberate and forward-looking relationship leveraging the comparative advantages of each Organization to maximize public health impact.
Home/ News/ Looking to the future: The Rockefeller Foundation and WHO identify priorities for global health collaboration
https://www.who.int/initiatives/act-accelerator
The Access to COVID-19 Tools (ACT) Accelerator
The Access to COVID-19 Tools (ACT) Accelerator, is a groundbreaking global collaboration to accelerate development, production, and equitable access to COVID-19 tests, treatments, and vaccines.
Launched at the end of April 2020, at an event co-hosted by the Director-General of the World Health Organization, the President of France, the President of the European Commission, and the Bill & Melinda Gates Foundation, the Access to COVID-19 Tools (ACT) Accelerator brings together governments, scientists, businesses, civil society, and philanthropists and global health organizations (the Bill & Melinda Gates Foundation, CEPI, FIND, Gavi, The Global Fund, Unitaid, Wellcome, the WHO, and the World Bank).
Following the ACT-Accelerator launch, UNICEF and PAHO became delivery partners for COVAX, the vaccines pillar.
These organizations have joined forces to speed up an end to the pandemic by supporting the development and equitable distribution of the tests, treatments and vaccines the world needs to reduce mortality and severe disease, restoring full societal and economic activity globally in the near term, and facilitating high-level control of COVID-19 disease in the medium term.
There is no time to waste in the fight against COVID-19. No-one is safe until everyone is safe.
Since April 2020, the ACT-Accelerator partnership, launched by WHO and partners, has supported the fastest, most coordinated, and successful global effort in history to develop tools to fight a disease. With significant advances in research and development by academia, private sector and government initiatives, the ACT-Accelerator is on the cusp of securing a way to end the acute phase of the pandemic by deploying the tests, treatment and vaccine the world needs.
This page is no longer updated. Please see COVID-19 vaccines
WHO had multiple roles within COVAX: It provided normative guidance on vaccine policy, regulation, safety, R&D, allocation, and country readiness and delivery
COVAX was a historic multilateral effort co-led by Gavi, the Vaccine Alliance, the Coalition for Epidemic Preparedness Innovations (CEPI), the World Health Organization (WHO) and UNICEF from 2020 through 2023. During the COVID-19 pandemic, COVAX aimed to accelerate the development and manufacture of COVID-19 vaccines and to guarantee fair and equitable access for every country in the world. COVAX came to a close on 31 December 2023. Read more
WHO’s Strategic Advisory Group of Experts (SAGE) on Immunization developed evidence-based immunization policy recommendations. Its Emergency Use Listing (EUL) / prequalification programmes ensured harmonized review and authorization across member states.
WHO provided global coordination and member state support on vaccine safety monitoring. It developed the target product profiles for COVID-19 vaccines and provided R&D technical coordination.
On behalf of the COVAX Partners, WHO developed a No-Fault Compensation Program to reduce the financial and liability exposure of the AMC92 and humanitarian agencies operating in the AMC92 and to facilitate access to compensation for eligible injured individuals.
WHO also led, together with UNICEF, the Country Readiness and Delivery workstream, which provided support to countries as they prepared to receive and administer vaccines.
Recognizing the urgency of turning vaccine doses into vaccinated, protected communities, WHO, UNICEF and Gavi, the Vaccine Alliance launched the COVID-19 Vaccine Delivery Partnership (CoVDP). The CoVDP built on existing resources to support the AMC 92 and focused foremost on the 34 countries that were at or below 10% coverage in January 2022. Working closely with countries to understand bottlenecks to vaccination, the CoVDP offered access to urgent operational funding, technical assistance and political engagement to rapidly scale up vaccination and monitor progress towards targets.
⚠️ Now that COVID-19 vaccines have been developed, the next major milestone will be ensuring people around the world are vaccinated, starting with the most vulnerable.
The rollout of COVID-19 vaccines presents fresh challenges, such as working to rapid timelines and reaching older populations that normally would not be a major focus of vaccination.
Addressing the operational challenges that arise from these developments is vital to ensuring vaccines are valued, trusted, easily available, and actively sought out. This is particularly important to achieve among under-reached groups, including women and girls.🚨
These tools were designed to respond to these challenges and support planning and implementation for COVID-19 vaccination. They offer practical guidance on a range of areas – from planning, to data gathering and evaluation, to specific strategies for community engagement and managing rumours and misinformation.
These materials were developed through an iterative, participatory process by the demand sub-group of the Country Readiness and Delivery (CRD) workstream of COVAX, the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator.
These tools are designed for national immunization programme managers, partner organizations, implementers and civil society representatives, and should be adapted and tailored for local contexts.
Updated versions will be posted, based on the latest evidence and learning.
What’s available?
COVID-19 vaccines: Demand Planning Tool
This operational tool provides an overview of key activities and considerations to achieve high acceptance and uptake of COVID-19 vaccines. It emphasizes the need for social listening and behavioural and social data collection and use, to guide the design and evaluation of targeted strategies to generate and sustain demand.
31 January 2021 Acceptance and demand for COVID-19 vaccines: Interim guidance
COVID-19 vaccines: Demand planning template (Excel sheet)
This communications plan template accompanies the Demand Planning Tool. It outlines the activities countries should consider when preparing to introduce COVID-19 vaccines. Countries can adapt this template and add activities to suit local contexts. Communications plans help to identify needs and avoid duplicating resources. They can also serve as an advocacy tool to leverage resources.
31 January 2021 Acceptance and demand for COVID-19 vaccines: communications plan template
COVID-19 vaccines: Data for action
Understanding how people think, feel and act in relation to vaccination is vital to informing the development of strategies to generate acceptance and uptake for the vaccines. Generating and using data on behavioural and social drivers (BeSD), with tools, such as surveys and interview guides, can help address the drivers and barriers to COVID-19 vaccines uptake. This guidebook will enable programmes to design, target and evaluate interventions to achieve greater impact with more efficiency, and to examine and understand trends over time.
COVID-19 vaccines: Community engagement guide
Community engagement should be at the centre of all COVID-19 vaccine introduction activities. This document contains tips and discussion topics to be considered in vaccine delivery and demand, as well as guiding steps to ensure a safe and community-centred approach.
31 January 2021 Conducting community engagement for COVID-19 vaccines: Interim guidance
COVID-19 vaccines: Misinformation management guide
Misinformation threatens the success of vaccination programs across the world. This guide aims to help organizations address the global ‘infodemic’ – an overabundance of information – through the development of strategic and well-coordinated national action plans to rapidly counter misinformation and build demand for vaccination; these plans can benefit from social listening. You can visit the guide’s web page here.
JULIMINATION 
Hinterlasse einen Kommentar